Kura Oncology Inc. Chief Executive Officer Troy Wilson acquired 100,000 shares of the company’s common stock on August 24, 2026, according to a regulatory filing. The purchases were executed at a weighted average price of $12.39 per share, totaling approximately $1.24 million. Trading activity ranged from $11.47 to $12.85 per share during the transaction period.
Wilson’s stake in Kura Oncology increased following the purchase. His direct holdings now stand at 435,456 shares, while indirect ownership through the One Fish Two Fish Revocable Trust rose to 479,194 shares. Additional indirect holdings via the Lorax Charitable Remainder Unitrust total 300,000 shares, bringing his combined direct and indirect ownership to more than 1.2 million shares.
The transaction follows Kura Oncology’s Q2 2026 financial results, which exceeded analyst expectations. The company reported adjusted losses of $0.77 per share, outperforming Wall Street’s forecasted loss of $0.88. Revenue reached $20.87 million, surpassing the expected $20.16 million, driven by early commercialization of the cancer drug KOMZIFTI.
Kura Oncology’s shares have gained roughly 62% over the past year and are trading near their 52-week high of $12.90. Analysts at Citizens reiterated a Market Outperform rating with a $24 price target, citing progress in the KOMZIFTI launch and an upward revision in earnings estimates. InvestingPro analysis, however, indicates the stock may be overvalued relative to its fair value estimate.
